 |
Corporate News
31-Dec-19
|
|
|
|
|
|
|
|
|
|
|
|
Alkem Laboratories to acquire assets related to API Dronabinol
|
|
From AbbVie Inc., USA
|
|
|
|
|
|
Alkem Laboratories has entered into an asset purchase agreement dated 30 December 2019 with AbbVie Inc., USA for acquisition of certain assets related to the active pharmaceutical ingredient, Dronabinol (Assets) which include domain names and trademarks related to "MARINOL", New Drug Application registration with USFDA for Marinol, logos, patents designs, know how, technical and manufacturing instructions, inventory,
manufacturing equipment and such items.
The cost of acquisition includes USD 10 million plus suitable working capital adjustments on closing.
|
|
|
|
Previous News |
Alkem Lab reports cyber incident
(
Hot Pursuit
-
15-Jan-24
10:22
)
|
|
|
Alkem Laboratories Ltd soars 1.6%, rises for third straight session
(
Hot Pursuit
-
17-May-24
13:05
)
|
|
|
Alkem Labs Q3 PAT falls over 13% YoY; EBITDA margin improves to 19.7%
(
Hot Pursuit
-
10-Feb-23
14:39
)
|
|
|
Alkem Laboratories Ltd spurts 0.08%, up for fifth straight session
(
Hot Pursuit
-
02-Dec-22
13:00
)
|
|
|
Alkem Laboratories Ltd gains for third straight session
(
Hot Pursuit
-
07-Dec-23
13:05
)
|
|
|
Alkem Laboratories Ltd spurts 1.87%
(
Hot Pursuit
-
22-Mar-23
13:05
)
|
|
|
Volumes soar at Alkem Laboratories Ltd counter
(
Hot Pursuit
-
25-Jan-24
11:00
)
|
|
|
Alkem Laboratories Ltd gains for third straight session
(
Hot Pursuit
-
27-Jul-21
13:05
)
|
|
|
Alkem Laboratories to announce Quarterly Result
(
Corporate News
-
06-Nov-21
10:03
)
|
|
|
Alkem Laboratories consolidated net profit declines 13.50% in the December 2022 quarter
(
Results
-
Announcements
10-Feb-23
14:36
)
|
|
|
Board of Alkem Laboratories appoints CEO
(
Corporate News
-
15-Sep-23
13:53
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|